glp-1 gila monster On a Mission to Heal Monsters Curious how a slow-moving lizard
Description
Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain mostbut not allof their weight loss, according to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
This case highlights the need for gradual insulin tapering and close monitoring while transitioning from insulin therapy to GIP/GLP-1 receptor agonists.
In addition, WHO included GLP-1 therapies on its Essential Medicines List (EML)
Significance statement ![Figure][1] ### Competing Interest Statement The authors have declared no competing interest
The controversial ad also hit a nerve with the pharma industry and lawmakers, who lashed the company for "deceptive" advertising.
